This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Clemons, K. V. Articles by Stevens, D. A. Search for Related Content PubMed PubMed Citation Articles by Clemons, K. V. Articles by Stevens, D. A.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, December 2005, p. 4867-4875, Vol. 49, No. 12
0066-4804/05/$08.00+0     doi:10.1128/AAC.49.12.4867-4875.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.

Comparative Efficacies of Conventional Amphotericin B, Liposomal Amphotericin B (AmBisome), Caspofungin, Micafungin, and Voriconazole Alone and in Combination against Experimental Murine Central Nervous System Aspergillosis

California Institute for Medical Research,¹ Department of Medicine, Division of Infectious Diseases, Santa Clara Valley Medical Center, San Jose, California 95128,² Department of Medicine, Division of Infectious Diseases and Geographic Medicine, Stanford University, Stanford, California 94305³

Received 20 June 2005/ Returned for modification 16 July 2005/ Accepted 27 September 2005

Central nervous system (CNS) aspergillosis is a severe disease that responds poorly to current therapies. The current studies examined the efficacies of several antifungal agents alone or in combination with a murine model of CNS aspergillosis. Immunosuppressed mice were infected intracerebrally with Aspergillus fumigatus and treated with an amphotericin B preparation, an echinocandin, or voriconazole (VCZ) given alone or in combination. Monotherapy studies showed that micafungin (MICA), caspofungin (CAS), VCZ, conventional amphotericin B (AMB), Abelcet (ABLC) (a lipid-carried AMB formulation; Enzon Pharmaceuticals, Inc.), and AmBisome (AmBi) (liposomal AMB; Gilead Sciences, Inc.) were efficacious. However, doses of AmBi above 15 mg/kg of body weight showed reduced efficacy. Neither MICA nor CAS showed dose responsiveness at the doses tested (1, 5, or 10 mg/kg). Only the 40-mg/kg dose of VCZ was effective. AmBi and ABLC showed dose responsiveness, with 10-mg/kg doses causing a significant reduction in fungal burden; they had equivalent activities at the 10-mg/kg dose. Suboptimal dosages of AmBi in combination with MICA, CAS, or VCZ were effective in prolonging survival. However, significantly enhanced activity was demonstrated only with AmBi and VCZ in combination. AmBi in combination with MICA or CAS showed a trend toward enhanced activity, but the combination was not significantly superior to monotherapy. The use of AmBi with CAS or VCZ at optimal doses did not improve efficacy. Cure was not attained with any dosage combinations. These results indicate that AmBi in combination with VCZ may be superior for treatment of CNS aspergillosis; combinations of AmBi and MICA or CAS were not antagonistic and may have a slight benefit.

This article has been cited by other articles:

• Serena, C., Marine, M., Quindos, G., Carrillo, A. J., Cano, J. F., Pastor, F. J., Guarro, J. (2008). In Vitro Interactions of Micafungin with Amphotericin B against Clinical Isolates of Candida spp.. Antimicrob. Agents Chemother. 52: 1529-1532 [Abstract] [Full Text]  
• Meletiadis, J., Antachopoulos, C., Stergiopoulou, T., Pournaras, S., Roilides, E., Walsh, T. J. (2007). Differential Fungicidal Activities of Amphotericin B and Voriconazole against Aspergillus Species Determined by Microbroth Methodology. Antimicrob. Agents Chemother. 51: 3329-3337 [Abstract] [Full Text]  
• Meletiadis, J., Stergiopoulou, T., O'Shaughnessy, E. M., Peter, J., Walsh, T. J. (2007). Concentration-Dependent Synergy and Antagonism within a Triple Antifungal Drug Combination against Aspergillus Species: Analysis by a New Response Surface Model. Antimicrob. Agents Chemother. 51: 2053-2064 [Abstract] [Full Text]  
• O'Shaughnessy, E. M., Meletiadis, J., Stergiopoulou, T., P. Demchok, J., Walsh, T. J. (2006). Antifungal interactions within the triple combination of amphotericin B, caspofungin and voriconazole against Aspergillus species. J Antimicrob Chemother 58: 1168-1176 [Abstract] [Full Text]  
• Spellberg, B., Schwartz, J., Fu, Y., Avanesian, V., Adler-Moore, J., Edwards, J. E. Jr, Ibrahim, A. S. (2006). Comparison of antifungal treatments for murine fusariosis. J Antimicrob Chemother 58: 973-979 [Abstract] [Full Text]  
• Clemons, K. V., Parmar, R., Martinez, M., Stevens, D. A. (2006). Efficacy of Abelcet alone, or in combination therapy, against experimental central nervous system aspergillosis. J Antimicrob Chemother 58: 466-469 [Abstract] [Full Text]  
• Leroy, P., Smismans, A., Seute, T. (2006). Invasive Pulmonary and Central Nervous System Aspergillosis After Near-Drowning of a Child: Case Report and Review of the Literature. Pediatrics 118: e509-e513 [Abstract] [Full Text]